Quote | Bolt Biotherapeutics Inc. (NASDAQ:BOLT)
Last: | $1.16 |
---|---|
Change Percent: | 0.02% |
Open: | $1.2 |
Close: | $1.16 |
High: | $1.21 |
Low: | $1.15 |
Volume: | 13,256 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Bolt Biotherapeutics Inc. (NASDAQ:BOLT)
2024-03-21 16:54:19 ET More on Bolt Biotherapeutics Seeking Alpha’s Quant Rating on Bolt Biotherapeutics Historical earnings data for Bolt Biotherapeutics Read the full article on Seeking Alpha For further details see: Bolt Biotherapeutics GAAP EPS...
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones – BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balanc...
Message Board Posts | Bolt Biotherapeutics Inc. (NASDAQ:BOLT)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $BOLT News Article - Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the My | whytestocks | investorshangout | 05/27/2022 3:51:00 PM |
whytestocks: $BOLT News Article - Bolt Biotherapeutics Inc.: The Winning Streak Continues (BOLT) | whytestocks | investorshangout | 04/06/2022 6:25:50 PM |
whytestocks: $BOLT News Article - Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Dir | whytestocks | investorshangout | 12/16/2021 1:45:57 PM |
whytestocks: $BOLT News Article - Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 | whytestocks | investorshangout | 12/02/2021 1:20:50 PM |
whytestocks: $BOLT News Article - Bolt Biotherapeutics to Present Updates on Three Pipeline Programs | whytestocks | investorshangout | 10/01/2021 12:45:50 PM |
News, Short Squeeze, Breakout and More Instantly...
Bolt Biotherapeutics Inc. Company Name:
BOLT Stock Symbol:
NASDAQ Market:
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones – BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balanc...
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44 th Annual He...
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization...